GeneDx is trading 21.7% down at $56.00 in pre-market, with the cause of the October 7 decline unclear.
- No verified company-specific announcement explaining the move appeared in available search results; the latest surfaced company release was its August 2026 quarterly results.
- The Fly’s company-news listing showed no October 7 catalyst.
- The supplied market snapshot was mixed, with major indexes near flat and futures modestly lower; it does not establish a broad-market explanation.